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Introduction: Recently, the STAR study showed that raloxifene works at least as 
well as tamoxifen in preventing breast cancer. It is of interest to know whether 
raloxifene may be used in the treatment of breast cancer and whether it would be 
effective in those who have developed resistance to other anti- estrogens. 
Methods: Estrogen receptor positive (er+) and negative (er-) breast cancer cells 
were exposed to tamoxifen, raloxifene or faslodex for 48 hours and the efficacy 
and potency of these drugs determined. MCF-7 breast cancer sub-lines lines 
resistant to tamoxifen (TAMR), raloxifene (RALR) or faslodex (FASR) were 
developed and used to determine cross-resistance among anti-estrogens 
Results: The efficacy of tamoxifen, raloxifene, and faslodex in inhibiting the 
proliferation of MCF-7 estrogen receptor positive er+ breast cancer were 
equivalent though theirs potencies differed. However, anti-estrogens were unable 
to inhibit the growth of er- breast cancer cells. TAMR sub-lines were resistant to 
raloxifene and faslodex, while FASR sub-lines were resistant to tamoxifen and 
raloxifene. RALR sub-lines however, were sensitive to treatment with tamoxifen 
in vitro and in vivo. Conclusions: The anti-estrogens tamoxifen, raloxifene and 
faslodex are equally efficacious in inhibiting breast cancer growth in er+ tumors. 
RALR sub-lines are sensitive to tamoxifen treatment. 
 





Breast cancer is the most common malignant neoplasm in women worldwide and 
in the United States.1 It is estimated that there are about 45,000 deaths in 
women and 400 deaths in men from breast cancer each year in the United 
States.2 The number one risk factor in the development of breast cancer in 
women is the life time exposure to estrogen.3,4 Estrogens act in human breast 
tissue by promoting the proliferation of human breast cells. The selective 
estrogen receptor modulator (SERM) tamoxifen (trans-1-(4-beta-
dimethylaminoethoxyphenyl)- 1,2-diphenylbut-1-ene), which is currently the most 
commonly used hormonal treatment for breast cancer has been shown to be 
effective in treating patients with advanced disease as an adjuvant in treating 
patients with primary breast carcinoma and as a preventative agent in those 
patients at high risk for developing breast carcinoma. Tamoxifen is effective in 
estrogen receptor positive breast cancers and there is also some evidence to 
suggest that it may inhibit the growth of estrogen receptor negative breast 
carcinomas5. However, resistance to tamoxifen inevitably occurs with 2-5 years 
after the beginning of treatment with no evidence suggesting a beneficial use 
after 5 years6,7. In addition, tamoxifen use is associated with a significant 
increase in endometrial carcinoma and tumor flare 8,9. Recently, it was reported 
that raloxifene ([6-hydroxy-2-(4- hydroxyphenyl)benzo[benzo[b]thien-3yl]-[4-2-(1- 
piperidinyl)ethoxy]phenyl]-hydrochloride) was at least as effective as tamoxifen in 
preventing breast cancer without the associated increased risk of endometrial 
carcinoma10. In this paper, we evaluate the ability of raloxifene to inhibit breast 
cancer proliferation in comparison to tamoxifen and faslodex and investigate 




Cells and Reagents: MCF-7 and MDA-MB-436 human breast cancer cells were 
obtained from American Type Tissue Culture in Manassas VA. Cells were grown 
in Dulbecco’s Modified Eagles Media (DMEM) with 10% fetal bovine serum 
(FBS), in a 5% CO2 incubator in 37oC. Cells at 80-85% confluence were 
trypsinized, washed with phosphate buffer solution (PBS) and plated for each 
experiment. Tamoxifen was obtained through Sigma-Aldrich, St. Louis, MO, 
raloxifene from Eli-Lilly, Indianapolis, IN, and faslodex (7- alpha-[9-(4,4,5,5,5-
penta fluoropentylsul- phinyl)nonyl]estra-1,3,5-(10)- triene-3,17-beta- diol) from 
Tocris-Cookson, Ellisville, MO. Measuring cellular proliferation: 25,000 cells were 
plated in 12 well costar flasks. After 4 hours, anti-estrogen was added and the 
cells were incubated for 48 hours. The cells were then treated sequentially with 
1% thiazolyl blue tetrazolium 20 minutes followed by 2-propanol for 30 minutes. 
Absorption was read with the Perkin-Elmer 1420 multi-label counter. Each data 
point on each curve was replicated at least 10 times. 
 
Establishment of MCF-7 cell sub-lines partially resistant to anti-estrogens: 4-5 
million MCF-7 cells were placed in 75 cm 2 Costar culture flasks with 20 ml of 
DMEM and 10 % FBS with either10 µM tamoxifen, 10 µM raloxifene or 0.1 µM 
faslodex. The cells were subcultivated every 3 days for 2-3 months, with at least 
1 million cells being placed in each of the flasks. The cells were tested for anti-
estrogen resistance by measuring their inhibition of growth in the presence of 
anti-estrogen after each fifth passage. 
 
Tumor allograft studies: 5 million raloxifene resistant sub-lines were implanted 
subcutaneously and bilaterally in the flanks of nude mice. The nude mice were 
fed water enriched with 8 mg/L of estrone daily. There were five mice in each of 
the control or treatment groups. Treatments were initiated when measurable 
tumors were present in all mice. Mice received either vehicle, tamoxifen at 2 mg/ 




Inhibition of breast cancer proliferation: In the first set of experiments, we 
evaluated the ability of the anti-estrogens tamoxifen, raloxifene and faslodex to 
inhibit MCF-7 estrogen receptor positive (er+) breast cancer growth. The efficacy 
(Emax) of the anti-estrogens as measured by maximum inhibition of MCF-7 cell 
growth was 30.2 ± 2.1 % tamoxifen, 30.75 ± 2.9 % raloxifene and 29.0 ± 2.6 % 
faslodex respectively. The potency of these anti-estrogens, as defined by the 
amount of drug needed to produce 0.5 of the maximum efficacy are, 0.479 µM 
tamoxifen, 0.355 µM raloxifene, and 0.013 µM faslodex. That is faslodex was 
36.8 times as potent as tamoxifen and 27.3 times as potent as raloxifene in its 
ability to inhibit MCF-7 growth, while, raloxifene was 1.3 times as potent as 
tamoxifen (Fig 1). Next, we wanted to see if anti-estrogens could inhibit er- breast 
cancer cells as reported in some articles5. In order to improve clinical relevance 
tamoxifen, raloxifene, and faslodex were dissolved in human blood at various 
concentrations until crystals or precipitation was seen under microscopy. 
Crystallization was observed at slightly over 10 µM for tamoxifen and raloxifene 
and at 0.11 µM for faslodex respectively. It was assumed that these levels might 
represent approximately the maximum dose available in vivo. A literature search, 
found that the maximum reported blood level reported for tamoxifen was about 4-
5 µM, consistent with our model 11. er- MDA-MB-436 breast cancer cells were 
exposed to vehicle, 10 µM tamoxifen, 10 µM raloxifene or 0.1 µM µM faslodex for 
48 hours. There was no inhibition of MDA-MB-436 proliferation observed, 
differing from previous reports. It was noted however that in these earlier reports, 
25 µM to 1000 µM concentrations were used, an amount of drug that cannot be 
obtained in vivo, these earlier reports may have represented a clinically non- 
relevant approach. 
 
Anti-estrogen cross resistance: MCF-7 sub- lines including (TAMR) 83.4 fold 
resistant, raloxifene (RALR) 190.8 fold resistant and faslodex (FASR) 87.0 fold 
resistant, were developed through continuous exposure to their respective anti-
estrogen. The TAMR sub-lines were exposed to raloxifene or faslodex for 48 
hours and the inhibition of breast cancer proliferation was measured by MTT 
assay. TAMR cells were 3.1 fold and 1.5 fold resistant to raloxifene and faslodex 
respectively. Next, RALR sub-lines were exposed to tamoxifen and faslodex. 
Interestingly, we found that the RALR sub-line was 22 fold as sensitive to 
inhibition by tamoxifen as wild type MCF-7 cells. The RALR sub-lines were 2.6 
fold resistant to faslodex. Additionally it was found that FASR sub-lines were 1.9 
and 1.5 fold resistant to tamoxifen and raloxifene respectively. Hence, cross 
resistance was present for nearly all combinations of treatment except, for the 
apparent sensitivity of RALR sub-lines to tamoxifen. We next tested this apparent 
in vitro sensitivity of the RALR sub- lines to tamoxifen in vivo. 
 
Raloxifene resistant (RALR) xenografts treated with tamoxifen: RALR sub-lines 
were implanted subcutaneously on the flanks of five nude mice per treatment 
group, mice were fed per os, either vehicle, raloxifene or tamoxifen daily. The 
tumor size was measured every other day with calipers. There was no significant 
difference between the mean tumor size between the control (treated with 
vehicle) mice and those exposed daily to raloxifene. However, there was a 
significant difference between the mean tumor size of the control mice and those 
mice given tamoxifen daily. At week 28, the tamoxifen treated tumors were 
approximately 25 % smaller. Necroscopy of the mice however, indicated a fatty 




Tamoxifen remains a front line agent for women who are at high risk for 
developing breast cancer or who are at risk for re-occurrence. However, 
tamoxifen also increases the risk of endometrial carcinoma. The STAR study, 
which recently, found that raloxifene is just as effective as tamoxifen in 
preventing cancer is welcome news as this drug does not impose the increased 
risk of endometrial carcinoma and is also used as a potent drug for osteoporosis 
found in post- menopausal women 12. However, could raloxifene also be useful 
as a therapy for er+ breast cancer? The in vitro studies presented here indicate 
that raloxifene is at least as efficacious as tamoxifen and the steroidal anti- 
estrogen faslodex in inhibiting breast cancer proliferation. None of the anti-
estrogens evaluated here however, were able to inhibit the growth of er- tumors. 
The next question was that since many women who take tamoxifen for breast 
cancer will inevitably become resistant to treatment with tamoxifen in two years, 
would these resistant tumors be susceptible to raloxifene or perhaps faslodex? 
The results here indicated that these tamoxifen resistant tumors would have 
partial resistance to raloxifene and faslodex. Yet, this increased resistance to 
these anti-hormones might not prevent the clinical treatment with raloxifene or 
faslodex of tamoxifen resistant tumors as the cross resistance is minor. One 
might simply increase the dosage of either raloxifene or faslodex in tamoxifen 
resistant tumors. Clinically, speaking this may be done when resistance is less 
than ten fold for a particular drug. Partial cross resistance to tamoxifen and 
raloxifene was also observed by faslodex resistant cells lines. Again, the cross 
resistance was mild but, present. The same principle then might apply in treating 
breast cancer tumors that have become resistant to faslodex, that is, one could 
increase the amount of an alternative anti-estrogen. This might be especially 
important in pre-menopausal women with er+ breast cancer as aromatase 
inhibitors in this group tend to be ineffective and hence, aromatase are approved 
only for post- menopausal women13. In vitro and in vivo studies presented here 
suggest that at least some raloxifene resistant breast cancers might be sensitive 
to tamoxifen. This in turn implies that one possible treatment protocol would be to 
start a patient on raloxifene and after either a relapse or progression one could 
switch the patient to tamoxifen. Caution must be taken however, as it is assumed 
that the raloxifene resistant cell lines developed in vitro in this study are similar to 
those which develops in a patients after continuous exposure to anti-estrogen. It 
is suggested that further studies include the use of breast cancer tumor biopsies 







The efficacy of the anti-estrogens tamoxifen, raloxifene and faslodex are similar, 
however, their potencies differ. Mild cross resistance generally exist between 
anti-estrogens though RALR sub-lines remained sensitive to tamoxifen. Whether, 
the cross-resistance observed precludes the use of alternative anti-estrogens 










The anti-estrogen dose response curve. The percent inhibition of MCF-7 breast cancer cell growth by 
faslodex, raloxifene or tamoxifen versus the log of the concentration of anti-estrogen is represented above. 
Solid circles and a solid line represents the faslodex curve, inverted triangles and dashed line represents the 






















Treatment of raloxifene resistant xenografts with tamoxifen. Raloxifene resistant sub-lines (RALR) were 
exposed to vehicle (solid circles and solid line), raloxifene (open circles and dotted line) or tamoxifen 
(inverted triangles and dashed line) daily for 28 weeks. The y-axis represents the mean tumor size of 10 
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